Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Obstetrics and Gynecology, The Second Hospital of Dalian Medical University, Dalian, China.
J Transl Med. 2021 Sep 8;19(1):382. doi: 10.1186/s12967-021-03057-0.
Glycolysis affects tumor growth, invasion, chemotherapy resistance, and the tumor microenvironment. In this study, we aimed to construct a glycolysis-related prognostic model for ovarian cancer and analyze its relationship with the tumor microenvironment's immune cell infiltration.
We obtained six glycolysis-related gene sets for gene set enrichment analysis (GSEA). Ovarian cancer data from The Cancer Genome Atlas (TCGA) database and two Gene Expression Omnibus (GEO) datasets were divided into two groups after removing batch effects. We compared the tumor environments' immune components in high-risk and low-risk groups and analyzed the correlation between glycolysis- and immune-related genes. Then, we generated and validated a predictive model for the prognosis of ovarian cancer using the glycolysis-related genes.
Overall, 27/329 glycolytic genes were associated with survival in ovarian cancer, 8 of which showed predictive value. The tumor cell components in the tumor microenvironment did not differ between the high-risk and low-risk groups; however, the immune score differed significantly between groups. In total, 13/24 immune cell types differed between groups, including 10 T cell types and three other immune cell types. Eight glycolysis-related prognostic genes were related to the expression of multiple immune-related genes at varying degrees, suggesting a relationship between glycolysis and immune response.
We identified eight glycolysis-related prognostic genes that effectively predicted survival in ovarian cancer. To a certain extent, the newly identified gene signature was related to the tumor microenvironment, especially immune cell infiltration and immune-related gene expression. These findings provide potential biomarkers and therapeutic targets for ovarian cancer.
糖酵解影响肿瘤的生长、侵袭、化疗耐药性和肿瘤微环境。在这项研究中,我们旨在构建一个卵巢癌糖酵解相关的预后模型,并分析其与肿瘤微环境免疫细胞浸润的关系。
我们获得了 6 个糖酵解相关基因集进行基因集富集分析(GSEA)。从癌症基因组图谱(TCGA)数据库和两个基因表达综合数据库(GEO)中获取卵巢癌数据,在去除批次效应后将数据分为两组。我们比较了高风险和低风险组肿瘤环境中的免疫成分,并分析了糖酵解和免疫相关基因之间的相关性。然后,我们使用糖酵解相关基因生成并验证了预测卵巢癌预后的模型。
总的来说,在卵巢癌中,有 27/329 个糖酵解基因与生存相关,其中 8 个具有预测价值。肿瘤微环境中肿瘤细胞成分在高风险和低风险组之间没有差异;然而,免疫评分在两组之间有显著差异。总的来说,13/24 种免疫细胞类型在两组之间存在差异,包括 10 种 T 细胞类型和三种其他免疫细胞类型。八个糖酵解相关预后基因与多种免疫相关基因的表达呈不同程度的相关,提示糖酵解与免疫反应之间存在关系。
我们确定了八个与卵巢癌生存相关的糖酵解相关预后基因。在一定程度上,新鉴定的基因特征与肿瘤微环境有关,特别是免疫细胞浸润和免疫相关基因表达。这些发现为卵巢癌提供了潜在的生物标志物和治疗靶点。